Global Valsartan Market Research Report 2022

Due to the COVID-19 pandemic, the global Valsartan market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Valsartan market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Valsartan landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

40 mg Tablets accounting for % of the Valsartan global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hypertension segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.

The global major manufacturers of Valsartan include Novartis, Sun Pharmaceutical, Teva, Mylan, Alembic Pharmaceuticals, Lupin, Aurobindo Pharma, Macleods Pharmaceuticals and HETERO, etc. In terms of revenue, the global 3 largest players have a % market share of Valsartan in 2021.

This report focuses on Valsartan volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Valsartan market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Global Valsartan Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.



Segment by Type


40 mg Tablets

80 mg Tablets

160 mg Tablets

320 mg Tablets



Segment by Application


Hypertension

Heart Failure

Heart Attack


By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE



By Company


Novartis

Sun Pharmaceutical

Teva

Mylan

Alembic Pharmaceuticals

Lupin

Aurobindo Pharma

Macleods Pharmaceuticals

HETERO

Torrent Pharmaceuticals

Huaren Pharmaceutical

Jubilant Pharma

Amneal Pharmaceuticals

Zhejiang Huahai Pharmaceutical

Square Pharmaceuticals

Unichem Laboratories

LG Life Sciences